01 / DESIGN
What was studied?
An ongoing randomized, double-blind, placebo-controlled trial enrolled people with biopsy-defined MASH and stage F2 or F3 fibrosis. This publication reported a planned analysis of the first 800 participants at week 72, within a longer study.
02 / FINDINGS
What did the researchers report?
Semaglutide improved the reported histologic endpoints, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis without worsening steatohepatitis. These outcomes describe the liver-biopsy assessment at the analyzed time point.
03 / LIMITS
How should it be interpreted?
An interim histology result does not alone establish long-term prevention of liver failure, transplantation or death. The population had specified disease and fibrosis stages. The findings relate to the pharmaceutical trial product and should not be used as catalog-material efficacy claims.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.